Psilocybin

Generic Name: Psilocybin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₂O_₄P

CAS Number: 520-52-5

Unique Ingredient Identifier: 2RV7212BP0

Background: Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Psilocybin for Enhanced Analgesia in Chronic NEuropathic PAIN

Phase 2

Not yet recruiting

Conditions: Chronic Neuropathic Pain
Pain Management

Interventions: Drug: Psilocybin
Drug: Active Placebo

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 30

Registration Number: NCT06731335

Locations: 🇨🇦
St. Michael's Hospital. Unity Health Toronto, Toronto, Ontario, Canada

Psilocybin for Treatment-Resistant Depression in Autism With Pre-Post Brain and Cognitive Measurement to Understand Mechanisms

Phase 1

Not yet recruiting

Conditions: Treatment Resistant Depression
Autism Spectrum Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 20

Registration Number: NCT06731621

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression

Phase 2

Not yet recruiting

Conditions: Bipolar II Disorder
Depression, Bipolar
Suicidality

Interventions: Drug: Psilocybin
Behavioral: Therapeutic Support

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 10

Registration Number: NCT06706232

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

The RECAP2 Study: Midazolam and Psilocybin

Phase 1

Not yet recruiting

Conditions: Psilocybin

Interventions: Drug: Psilocybin
Drug: Saline
Drug: Midazolam

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-26

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 60

Registration Number: NCT06692192

Psilocybin-assisted Treatment for Cannabis Use Disorder

Phase 1

Recruiting

Conditions: Cannabis Use Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2024-10-28

Last Posted Date: 2024-11-11

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 12

Registration Number: NCT06660381

Locations: 🇺🇸
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Early Phase 1

Not yet recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Psilocybin

First Posted Date: 2024-10-24

Last Posted Date: 2024-12-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 24

Registration Number: NCT06656702

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression

Not Applicable

Recruiting

Conditions: Depressive Disorder
Depressive Disorder, Treatment-Resistant
Hallucinogens
Reinforcement, Psychology

Interventions: Drug: Psilocybin
Other: MRI

First Posted Date: 2024-10-21

Last Posted Date: 2024-11-22

Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Target Recruit Count: 12

Registration Number: NCT06650800

Locations: 🇫🇷
CHU de Nîmes, Hôpital Universitaire Carémeau, Nimes, France

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients with Psychogenic Nonepileptic Seizures

Not Applicable

Not yet recruiting

Conditions: Psychogenic Nonepileptic Seizures
Psilocybin

Interventions: Drug: Psilocybin
Other: MRI

First Posted Date: 2024-10-17

Last Posted Date: 2024-10-17

Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Target Recruit Count: 10

Registration Number: NCT06647056

Locations: 🇫🇷
CHU de Nîmes, Hôpital Universitaire Carémeau, Nimes, France

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphatic System Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Behavioral: Behavioral Intervention
Behavioral: Group Therapy
Drug: Psilocybin
Other: Questionnaire Administration

First Posted Date: 2024-10-16

Last Posted Date: 2024-12-11

Lead Sponsor: University of Washington

Target Recruit Count: 16

Registration Number: NCT06644170

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Psilocybin
Drug: Placebo

First Posted Date: 2024-10-16

Last Posted Date: 2024-12-12

Lead Sponsor: MycoMedica Life Sciences PBC

Target Recruit Count: 24

Registration Number: NCT06643637

Locations: 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy